| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_282d8844066f5f683bc2463742373508 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2007-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_facdee6ca72554a457e4a23ea312dbc4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c4f1b69f3734fe809bd5a93e3183454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b48441077449755e10bff22435aa315a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcac1a19dabbbcb65690dc9aad2e1fe0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_147c3fe20a3f31b6f6f17f378bb68ada
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c491acac69a358dfdf54731995c489a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_337e291cbcf917a5b2efc529a80c73c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65e2e91de547503f6c62a6d363b906c2 |
| publicationDate |
2012-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2420514-A1 |
| titleOfInvention |
Targeted binding agents directed to PDGFR-alpha and uses thereof |
| abstract |
Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha. |
| priorityDate |
2006-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |